Market Overview

Jim Cramer Gives His Opinion On Allergan, USG And Arena Pharmaceuticals

Related AGN
FDA Panel Reviews Johnson & Johnson's Treatment-Resistant Depression Candidate: What To Expect
Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates
U.S. healthcare spending to rise 5.5% per annum over next decade (Seeking Alpha)
Related USG
Earnings Scheduled For February 14, 2019
Difficult Q4 Diminishes Raymond James' Bullishness On Drywall Producers
Merger Arbitrage Analysis And Spread Performance - February 17, 2019 (Seeking Alpha)

On CNBC's "Mad Money Lightning Round", Jim Cramer said Allergan plc (NYSE: AGN) is an inexpensive stock and he would buy it. He explained that the stock is struggling at the moment, because the company has a drug that might come off patent.

Cramer would wait for USG Corporation (NYSE: USG) to come down. He would buy it after it pulls back.

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) has reinvented itself and now the stock is undervalued, thinks Cramer. He believes the stock is good.

Posted-In: CNBC mad money Lightning Round Jim CramerMedia


Related Articles (ARNA + AGN)

View Comments and Join the Discussion!

22 Stocks Moving In Tuesday's Pre-Market Session

Wall Street's M&A Chatter From September 11: Western Digital-Toshiba, Pilgrim's Pride-Moy Park, Gigamon And More